Skip to content
Vitrakvi(larotrectinib)
Vitrakvi (larotrectinib) is a small molecule pharmaceutical. Larotrectinib was first approved as Vitrakvi on 2018-11-26. It is used to treat neoplasm drug resistance and neoplasm metastasis in the USA. It has been approved in Europe to treat abdominal neoplasms. It is known to target high affinity nerve growth factor receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
signs and symptoms pathological conditionsD013568
physiological phenomenaD010829
Trade Name
FDA
EMA
Vitrakvi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Larotrectinib sulfate
Tradename
Company
Number
Date
Products
VITRAKVIBayerN-211710 RX2018-11-26
1 products, RLD, RS
VITRAKVIBayerN-210861 RX2018-11-26
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
vitrakviNew Drug Application2019-07-26
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
neoplasm drug resistance—D019008—
neoplasm metastasisEFO_0009708D009362—
Agency Specific
FDA
EMA
Expiration
Code
LAROTRECTINIB SULFATE, VITRAKVI, BAYER HEALTHCARE
2025-11-26ODE-215, ODE-220, ODE-221
2023-11-26NCE
LAROTRECTINIB SULFATE, VITRAKVI, BAYER HLTHCARE
2025-11-26ODE-215, ODE-220, ODE-221
2023-11-26NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Larotrectinib Sulfate, Vitrakvi, Bayer Healthcare
100459912037-04-04U-2473
101371272037-04-04DP
106680722037-04-04DP
111917662037-04-04U-2471
114845352037-04-04U-2470
107995052036-08-15DS, DP
97824142035-11-16U-2471, U-2475
101728612035-11-16DS, DP
85132632029-12-23DS, DP
88656982029-10-21U-2469
91270132029-10-21DS, DP
94471042029-10-21U-2470
96767832029-10-21U-2469
100057832029-10-21U-2472
100470972029-10-21U-2474
107740852029-10-21U-2470
Larotrectinib Sulfate, Vitrakvi, Bayer Hlthcare
102859932035-11-16U-2470
108139362035-11-16U-2987
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EX: Other protein kinase inhibitors in atc
— L01EX12: Larotrectinib
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8023——48
GliomaD005910EFO_0000520—3———3
Non-hodgkin lymphomaD008228C85.9—3———3
Central nervous system neoplasmsD016543—3———3
Colorectal neoplasmsD015179—2———2
Multiple myelomaD009101C90.0—2———2
SarcomaD012509—2———2
NeuroblastomaD009447EFO_0000621—2———2
OsteosarcomaD012516—2———2
MedulloblastomaD008527—2———2
Show 29 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diffuse intrinsic pontine gliomaD0000804431————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLAROTRECTINIB
INNlarotrectinib
Description
Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.
Classification
Small molecule
Drug classtyrosine kinase inhibitors: tropomyosin receptor kinase (TRK) inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1
Identifiers
PDB—
CAS-ID1223403-58-4
RxCUI2105628
ChEMBL IDCHEMBL3889654
ChEBI ID—
PubChem CID46188928
DrugBankDB14723
UNII IDPF9462I9HX (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
NTRK1
NTRK1
Organism
Homo sapiens
Gene name
NTRK1
Gene synonyms
MTC, TRK, TRKA
NCBI Gene ID
4914
Protein name
high affinity nerve growth factor receptor
Protein synonyms
gp140trk, Neurotrophic tyrosine kinase receptor type 1, neurotrophic tyrosine kinase, receptor, type 1, Oncogene TRK, p140-TrkA, Trk-A, TRK1-transforming tyrosine kinase protein, tropomyosin receptor kinase A, Tropomyosin-related kinase A, Tyrosine kinase receptor, Tyrosine kinase receptor A
Uniprot ID
P04629
Mouse ortholog
Ntrk1 (18211)
high affinity nerve growth factor receptor (Q3UFB7)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,792 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
18,056 adverse events reported
View more details